Skip to main content
Top

Open Access 03-02-2025 | Atrial Fibrillation | ORIGINAL RESEARCH

Impact of left atrial myopathy and post-ablation remodeling on quality of life: a DECAAF II sub-analysis

Authors: Ghassan Bidaoui, Han Feng, Nour Chouman, Ala Assaf, Chanho Lim, Hadi Younes, Mayana Bsoul, Christian Massad, Francisco Tirado Polo, Yishi Jia, Yingshou Liu, Abboud Hassan, William Rittmeyer, Mario Mekhael, Charbel Noujaim, Amitabh C. Pandey, Swati Rao, Omar Kreidieh, Nassir F. Marrouche, Eoin Donnellan

Published in: Journal of Interventional Cardiac Electrophysiology

Login to get access

Abstract

Background

Atrial fibrillation (AF) is associated with adverse remodeling of the left atrium (LA). The impact of the extent of atrial myopathy and post-ablation remodeling on quality-of-life (QoL) outcomes has not been studied.

Objective

The aim of our study was to investigate the association between atrial myopathy and post-ablation remodeling on quality-of-life outcomes in patients with persistent AF.

Methods

We conducted an analysis of DECAAF II participants who underwent late-gadolinium enhancement MRI (LGE-MRI) before and after AF ablation. We assessed atrial myopathy and post-ablation atrial remodeling, scar formation, and fibrosis coverage with ablation. QoL metrics were assessed using the Short Form Survey (SF-36) and Atrial Fibrillation Severity Scale (AFSS). Uni- and multivariable regression models were developed for this analysis.

Results

Six hundred thirteen patients with persistent AF were included in our analyses. At baseline, AFSS burden and total AFSS score were 18.94 ± 7.35 and 12.24 ± 8.17, respectively. Following ablation, all QoL and AFSS metrics improved in both the pulmonary vein isolation (PVI) and MRI-guided fibrosis ablation groups. On average, one unit of post-ablation reduction in left atrial volume index (LAVI) was associated with an improvement of 0.085 in total AFSS score (p = 0.001), 0.01 in shortness of breath with activity (p < 0.001), 0.15 in AF burden (p < 0.001), − 0.016 in global well-being (p = 0.018), 0.519 in health change (p < 0.001), 0.19 in vitality (vitality (p = 0.01), and 0.27 in physical functioning (p = 0.001). Baseline fibrosis and residual fibrosis post-ablation were associated with improved vitality and general health.

Conclusion

Atrial myopathy and post-ablation atrial remodeling significantly impact QoL in patients with persistent AF undergoing ablation.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Benjamin EJ, Chen P-S, Bild DE, et al. Prevention of atrial fibrillation. Report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–18.CrossRefPubMedPubMedCentral Benjamin EJ, Chen P-S, Bild DE, et al. Prevention of atrial fibrillation. Report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–18.CrossRefPubMedPubMedCentral
4.
go back to reference Hirsh BJ, Copeland-Halperin Robert S, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism. J Am College Cardiol Am College Cardiol Foundation. 2015;65:2239–51.CrossRef Hirsh BJ, Copeland-Halperin Robert S, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism. J Am College Cardiol Am College Cardiol Foundation. 2015;65:2239–51.CrossRef
5.
go back to reference Schotten U, Neuberger H-R, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. Prog Biophys Mol Biol. 2003;82:151–62.CrossRefPubMed Schotten U, Neuberger H-R, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. Prog Biophys Mol Biol. 2003;82:151–62.CrossRefPubMed
6.
go back to reference McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81:825–32.CrossRefPubMed McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81:825–32.CrossRefPubMed
7.
go back to reference Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42:185–97.CrossRefPubMed Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42:185–97.CrossRefPubMed
8.
go back to reference Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol Hoboken: Wiley. 2008;19:762–8.CrossRef Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol Hoboken: Wiley. 2008;19:762–8.CrossRef
9.
go back to reference Terricabras M, Mantovan R, Jiang C, et al. Association between quality of life and procedural outcome after catheter ablation for atrial fibrillation: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2020;3:e2025473.CrossRefPubMedPubMedCentral Terricabras M, Mantovan R, Jiang C, et al. Association between quality of life and procedural outcome after catheter ablation for atrial fibrillation: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2020;3:e2025473.CrossRefPubMedPubMedCentral
10.
go back to reference Assaf AY, Noujaim C, Mekhael M, et al. Early remodeling of the left atrium following catheter ablation of atrial fibrillation: insights from DECAAFII. JACC Clin Electrophysiol. 2023;9:2253–62.CrossRefPubMed Assaf AY, Noujaim C, Mekhael M, et al. Early remodeling of the left atrium following catheter ablation of atrial fibrillation: insights from DECAAFII. JACC Clin Electrophysiol. 2023;9:2253–62.CrossRefPubMed
11.
go back to reference King JB, Azadani PN, Suksaranjit P, et al. Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:1311–21.CrossRefPubMed King JB, Azadani PN, Suksaranjit P, et al. Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:1311–21.CrossRefPubMed
12.
go back to reference Mohanty S, Della Rocca DG, Gianni C, et al. Predictors of recurrent atrial fibrillation following catheter ablation. Expert Rev Cardiovasc Therapy Taylor Francis. 2021;19:237–46.CrossRef Mohanty S, Della Rocca DG, Gianni C, et al. Predictors of recurrent atrial fibrillation following catheter ablation. Expert Rev Cardiovasc Therapy Taylor Francis. 2021;19:237–46.CrossRef
13.
go back to reference Marrouche NF, Greene T, Dean JM, Kholmovski EG, Boer LM, Mansour M, et al. Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: the DECAAF II trial: study design. J Cardiovasc Electrophysiol. 2021;32(4):916–24. https://doi.org/10.1111/jce.14957. Marrouche NF, Greene T, Dean JM, Kholmovski EG, Boer LM, Mansour M, et al. Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: the DECAAF II trial: study design. J Cardiovasc Electrophysiol. 2021;32(4):916–24. https://​doi.​org/​10.​1111/​jce.​14957.
14.
go back to reference Marrouche NF, Wazni O, McGann C, et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the DECAAF II randomized clinical trial. JAMA. 2022;327:2296–305.CrossRefPubMedPubMedCentral Marrouche NF, Wazni O, McGann C, et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the DECAAF II randomized clinical trial. JAMA. 2022;327:2296–305.CrossRefPubMedPubMedCentral
15.
go back to reference Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119:1758–67.CrossRefPubMedPubMedCentral Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119:1758–67.CrossRefPubMedPubMedCentral
16.
go back to reference Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002;143:984–90.CrossRefPubMed Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J. 2002;143:984–90.CrossRefPubMed
17.
go back to reference Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
20.
go back to reference Aliot E, Botto GL, Crijns HJ, Kirchhof P. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. EP Europace. 2014;16:787–96.CrossRef Aliot E, Botto GL, Crijns HJ, Kirchhof P. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. EP Europace. 2014;16:787–96.CrossRef
21.
go back to reference Mark DB. Assessing quality-of-life outcomes in cardiovascular clinical research. Nat Rev Cardiol Nature Publishing Group. 2016;13:286–308.CrossRef Mark DB. Assessing quality-of-life outcomes in cardiovascular clinical research. Nat Rev Cardiol Nature Publishing Group. 2016;13:286–308.CrossRef
22.
go back to reference Johnson BM, Wazni OM, Farwati M, et al. Atrial fibrillation ablation in young adults: measuring quality of life using patient-reported outcomes over 5 years. Circ Arrhythm Electrophysiol. 2023;16:e011565.CrossRefPubMedPubMedCentral Johnson BM, Wazni OM, Farwati M, et al. Atrial fibrillation ablation in young adults: measuring quality of life using patient-reported outcomes over 5 years. Circ Arrhythm Electrophysiol. 2023;16:e011565.CrossRefPubMedPubMedCentral
23.
go back to reference Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1275–85.CrossRefPubMedPubMedCentral Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1275–85.CrossRefPubMedPubMedCentral
24.
go back to reference Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010;55:2308–16.CrossRefPubMed Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010;55:2308–16.CrossRefPubMed
25.
go back to reference Jahnke C, Fischer J, Gerds-Li J-H, et al. Serial monitoring of reverse left-atrial remodeling after pulmonary vein isolation in patients with atrial fibrillation: a magnetic resonance imaging study. Int J Cardiol. 2011;153:42–6.CrossRefPubMed Jahnke C, Fischer J, Gerds-Li J-H, et al. Serial monitoring of reverse left-atrial remodeling after pulmonary vein isolation in patients with atrial fibrillation: a magnetic resonance imaging study. Int J Cardiol. 2011;153:42–6.CrossRefPubMed
26.
go back to reference Hof IE, Velthuis BK, Chaldoupi S-M, et al. Pulmonary vein antrum isolation leads to a significant decrease of left atrial size. Europace. 2011;13:371–5.CrossRefPubMed Hof IE, Velthuis BK, Chaldoupi S-M, et al. Pulmonary vein antrum isolation leads to a significant decrease of left atrial size. Europace. 2011;13:371–5.CrossRefPubMed
27.
go back to reference Beukema WP, Elvan A, Sie HT, Misier ARR, Wellens HJJ. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. Circulation. 2005;112:2089–95.CrossRefPubMed Beukema WP, Elvan A, Sie HT, Misier ARR, Wellens HJJ. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. Circulation. 2005;112:2089–95.CrossRefPubMed
28.
go back to reference Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019;321:1059–68.CrossRefPubMedPubMedCentral Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019;321:1059–68.CrossRefPubMedPubMedCentral
29.
go back to reference Gal P, Marrouche NF. Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. Eur Heart J. 2017;38:14–9.CrossRefPubMed Gal P, Marrouche NF. Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. Eur Heart J. 2017;38:14–9.CrossRefPubMed
30.
go back to reference Schilling R, Dhillon GS, Tondo C, et al. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE. EP Europace. 2021;23:851–60.CrossRef Schilling R, Dhillon GS, Tondo C, et al. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE. EP Europace. 2021;23:851–60.CrossRef
31.
go back to reference Reynolds MR, Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circulation: Cardiovasc Quality Outcomes Am Heart Assoc. 2010;3:615–23. Reynolds MR, Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circulation: Cardiovasc Quality Outcomes Am Heart Assoc. 2010;3:615–23.
Metadata
Title
Impact of left atrial myopathy and post-ablation remodeling on quality of life: a DECAAF II sub-analysis
Authors
Ghassan Bidaoui
Han Feng
Nour Chouman
Ala Assaf
Chanho Lim
Hadi Younes
Mayana Bsoul
Christian Massad
Francisco Tirado Polo
Yishi Jia
Yingshou Liu
Abboud Hassan
William Rittmeyer
Mario Mekhael
Charbel Noujaim
Amitabh C. Pandey
Swati Rao
Omar Kreidieh
Nassir F. Marrouche
Eoin Donnellan
Publication date
03-02-2025
Publisher
Springer US
Published in
Journal of Interventional Cardiac Electrophysiology
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-025-02002-1

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now